Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer

NCT00334815 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00334815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00334815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 15, 2006
Completion date
February 22, 2027
Enrollment
29 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma, lung adenosquamous carcinoma, lung large cell carcinoma, lung squamous cell carcinoma, minimally invasive lung adenocarcinoma, stage iiia lung non-small cell cancer ajcc v7, stage iiib lung non-small cell cancer ajcc v7